Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
57
NAGE Quote, Financials, Valuation and Earnings
Last price:
$6.60
Seasonality move
:
15.99%
Day range:
$6.54 - $6.82
52-week range:
$5.16 - $14.69
Dividend yield:
0%
P/E ratio:
27.09x
P/S ratio:
4.46x
P/B ratio:
7.44x
Volume:
977.1K
Avg. volume:
766.7K
1-year change:
19.38%
Market cap:
$525.9M
Revenue:
$99.6M
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$31.1M | $0.02 | 8.86% | -82.94% | $15.80 |
|
CAI
CAI International
|
-- | -- | -- | -- | -- |
|
CORT
Corcept Therapeutics, Inc.
|
$218.5M | $0.14 | 43.56% | 32.34% | $127.20 |
|
LQDA
Liquidia Corp.
|
$19.5M | -$0.35 | 2667.32% | -50.89% | $44.00 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$19.4M | -$0.38 | 440.82% | -39.26% | $7.00 |
|
TMDX
TransMedics Group, Inc.
|
$144.8M | $0.36 | 28.37% | 94.67% | $144.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$6.59 | $15.80 | $525.9M | 27.09x | $0.00 | 0% | 4.46x |
|
CAI
CAI International
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
CORT
Corcept Therapeutics, Inc.
|
$79.82 | $127.20 | $8.4B | 91.20x | $0.00 | 0% | 12.87x |
|
LQDA
Liquidia Corp.
|
$34.75 | $44.00 | $3B | -- | $0.00 | 0% | 42.90x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$4.13 | $7.00 | $2.1B | -- | $0.00 | 0% | 37.89x |
|
TMDX
TransMedics Group, Inc.
|
$123.06 | $144.73 | $4.2B | 49.71x | $0.00 | 0% | 8.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
4.14% | 1.676 | 0.41% | 3.21x |
|
CAI
CAI International
|
-- | 0.000 | -- | -- |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.063 | 0.07% | 2.85x |
|
LQDA
Liquidia Corp.
|
90.03% | 0.315 | 10.09% | 1.88x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
7.29% | 1.657 | 3.43% | 4.27x |
|
TMDX
TransMedics Group, Inc.
|
59.39% | 2.406 | 13.56% | 6.86x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$21.9M | $4.2M | 35.7% | 37.74% | 12.46% | $3.7M |
|
CAI
CAI International
|
-- | -- | -- | -- | -- | -- |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
LQDA
Liquidia Corp.
|
$50.9M | $1.8M | -79.94% | -221.75% | 3.25% | -$10.7M |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
-$22.9M | -$172.2M | -72.69% | -80.23% | -3327.58% | -$117.6M |
|
TMDX
TransMedics Group, Inc.
|
$84.5M | $23.3M | 11.55% | 33.29% | 16.2% | $61.9M |
Niagen Bioscience, Inc. vs. Competitors
-
Which has Higher Returns NAGE or CAI?
CAI International has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of --. Niagen Bioscience, Inc.'s return on equity of 37.74% beat CAI International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M CAICAI International-- -- -- -
What do Analysts Say About NAGE or CAI?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 139.76%. On the other hand CAI International has an analysts' consensus of -- which suggests that it could fall by --. Given that Niagen Bioscience, Inc. has higher upside potential than CAI International, analysts believe Niagen Bioscience, Inc. is more attractive than CAI International.
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 CAICAI International0 0 0 -
Is NAGE or CAI More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison CAI International has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAGE or CAI?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CAI International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. CAI International pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or CAI?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are larger than CAI International quarterly revenues of --. Niagen Bioscience, Inc.'s net income of $4.6M is higher than CAI International's net income of --. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 27.09x while CAI International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.46x versus -- for CAI International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.46x 27.09x $34M $4.6M CAICAI International-- -- -- --
-
Which has Higher Returns NAGE or CORT?
Corcept Therapeutics, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 9.32%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About NAGE or CORT?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 139.76%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $127.20 which suggests that it could grow by 59.36%. Given that Niagen Bioscience, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 CORTCorcept Therapeutics, Inc.3 2 0 -
Is NAGE or CORT More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.
-
Which is a Better Dividend Stock NAGE or CORT?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or CORT?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Niagen Bioscience, Inc.'s net income of $4.6M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 27.09x while Corcept Therapeutics, Inc.'s PE ratio is 91.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.46x versus 12.87x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.46x 27.09x $34M $4.6M CORTCorcept Therapeutics, Inc.12.87x 91.20x $207.6M $19.4M
-
Which has Higher Returns NAGE or LQDA?
Liquidia Corp. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of -6.5%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Liquidia Corp.'s return on equity of -221.75%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M LQDALiquidia Corp.93.65% -$0.04 $221.2M -
What do Analysts Say About NAGE or LQDA?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 139.76%. On the other hand Liquidia Corp. has an analysts' consensus of $44.00 which suggests that it could grow by 26.62%. Given that Niagen Bioscience, Inc. has higher upside potential than Liquidia Corp., analysts believe Niagen Bioscience, Inc. is more attractive than Liquidia Corp..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 LQDALiquidia Corp.7 0 1 -
Is NAGE or LQDA More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.
-
Which is a Better Dividend Stock NAGE or LQDA?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or LQDA?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Liquidia Corp. quarterly revenues of $54.3M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Liquidia Corp.'s net income of -$3.5M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 27.09x while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.46x versus 42.90x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.46x 27.09x $34M $4.6M LQDALiquidia Corp.42.90x -- $54.3M -$3.5M
-
Which has Higher Returns NAGE or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of -3135.32%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B -
What do Analysts Say About NAGE or RXRX?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 139.76%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 69.49%. Given that Niagen Bioscience, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 RXRXRecursion Pharmaceuticals, Inc.1 5 0 -
Is NAGE or RXRX More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAGE or RXRX?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or RXRX?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 27.09x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.46x versus 37.89x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.46x 27.09x $34M $4.6M RXRXRecursion Pharmaceuticals, Inc.37.89x -- $5.2M -$162.3M
-
Which has Higher Returns NAGE or TMDX?
TransMedics Group, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 16.91%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat TransMedics Group, Inc.'s return on equity of 33.29%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M -
What do Analysts Say About NAGE or TMDX?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 139.76%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $144.73 which suggests that it could grow by 17.61%. Given that Niagen Bioscience, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 TMDXTransMedics Group, Inc.7 3 0 -
Is NAGE or TMDX More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 2.061, suggesting its more volatile than the S&P 500 by 106.067%.
-
Which is a Better Dividend Stock NAGE or TMDX?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or TMDX?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than TransMedics Group, Inc. quarterly revenues of $143.8M. Niagen Bioscience, Inc.'s net income of $4.6M is lower than TransMedics Group, Inc.'s net income of $24.3M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 27.09x while TransMedics Group, Inc.'s PE ratio is 49.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.46x versus 8.50x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.46x 27.09x $34M $4.6M TMDXTransMedics Group, Inc.8.50x 49.71x $143.8M $24.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 37.63% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.16% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 5.52% over the past day.
